WG
CPRX

Winton Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Winton Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.04M Buy
287,736
+220,016
+325% +$6.49M 0.29% 85
2026
Q1 		$1.68M Sell
67,720
-285,809
-81% -$6.81M 0.06% 362
2025
Q4 		$8.25M Buy
353,529
+298,862
+547% +$6.66M 0.28% 88
2025
Q3 		$1.08M Buy
54,667
+4,673
+9% +$96.1K 0.04% 430
2025
Q2 		$1.08M Sell
49,994
-6,769
-12% -$160K 0.06% 404
2025
Q1 		$1.38M Sell
56,763
-2,510
-4% -$56.5K 0.08% 229
2024
Q4 		$1.24M Buy
59,273
+4
+0% +$86 0.08% 215
2024
Q3 		$1.18M Sell
59,269
-5,126
-8% -$95K 0.08% 206
2024
Q2 		$997K Buy
64,395
+110
+0.2% +$1.71K 0.07% 241
2024
Q1 		$1.02M Buy
+64,285
New +$969K 0.07% 241
2023
Q2 		– Sell
-20,158
Closed -$334K – 836
2023
Q1 		$334K Buy
20,158
+5,597
+38% +$92.3K 0.02% 795
2022
Q4 		$271K Sell
14,561
-8,943
-38% -$138K 0.02% 807
2022
Q3 		$302K Buy
+23,504
New +$279K 0.02% 793
2021
Q4 		– Sell
-142,529
Closed -$755K – 1086
2021
Q3 		$755K Buy
142,529
+5,313
+4% +$29.1K 0.04% 649
2021
Q2 		$789K Buy
137,216
+14,797
+12% +$76.4K 0.04% 658
2021
Q1 		$564K Buy
122,419
+36,545
+43% +$145K 0.03% 817
2020
Q4 		$287K Buy
85,874
+26,640
+45% +$89.5K 0.02% 1065
2020
Q3 		$176K Buy
+59,234
New +$232K 0.01% 1361
2019
Q2 		– Sell
-12,454
Closed -$64K – 1152
2019
Q1 		$64K Buy
+12,454
New +$36.6K ﹤0.01% 1046

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winton Group's CPRX Position: Q2 2026 in Review

Winton Group increased its Catalyst Pharmaceutical (CPRX) stake by 325% in Q2 2026, buying an estimated $6.49M and bringing the position to 287,736 shares worth $9.04M. The position accounts for 0.29% of the portfolio, ranked #85.

Winton Group first reported a position in CPRX in Q1 2019 and has held it in 19 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Winton Group held 287,736 shares of Catalyst Pharmaceutical worth $9.04M as of Q2 2026.
  • Winton Group bought 220,016 Catalyst Pharmaceutical shares in Q2 2026, an estimated $6.49M.
  • Catalyst Pharmaceutical made up 0.29% of Winton Group's portfolio in Q2 2026, its #85 holding.
  • Winton Group first reported a position in Catalyst Pharmaceutical in Q1 2019 and has held it in 19 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.